about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

GSK spin­out KaNDy rais­es $32M to fund a break­through shot at a wom­en's health drug

7 years ago
Financing
Startups

Tetraphase plots Q4 launch for first an­tibi­ot­ic af­ter long-await­ed OK for er­ava­cy­cline

7 years ago
Pharma

No­var­tis qui­et­ly hands top­i­cal treat­ment for rare dis­ease to Life­Max — lat­est in a string of out-li­cens­ing deals

7 years ago
R&D
Pharma

Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

7 years ago
Financing
China

Chi­na Bi­o­log­ic re­jects $3.9B buy­out bid from ex-CEO; Leo Phar­ma bags atopic der­mati­tis drug for $17M up­front

7 years ago
News Briefing

E-Scape Bio in­stalls per­ma­nent CEO Julie Anne Smith; Fa­ther pass­es reins to son at Al­le­gro Oph­thalmics

7 years ago
Peer Review

New­ly part­nered with blue­bird, Grit­stone seeks $80M IPO in fi­nal dash for clin­ic

7 years ago
Financing

Hit by sur­prise set­back, As­traZeneca scram­bles to ex­plain why its two-in-one COPD in­haler was beat­en by GSK ri­val

7 years ago
R&D

New­born bio­bet­ter, biosim­i­lar mak­er Mabpharm pitch­es the lat­est biotech IPO in Hong Kong

7 years ago
Financing
China

Bris­tol-My­ers will sell Op­di­vo in Chi­na at half of US cost, set­ting prece­dent for check­point wave — re­port

7 years ago
China
Pharma

Rex­ahn inks Keytru­da com­bo col­lab­o­ra­tion in breast can­cer; Achillion hires uniQure's Steven Ze­lenkofske as new CMO

7 years ago
News Briefing

Cam­bridge in­ves­ti­ga­tors ze­ro in on a new, niche drug tar­get for lung can­cer

7 years ago
Discovery

Right on the heels of $150M raise, As­cen­t­age files the lat­est in a rush of HKEX biotech IPOs — but is the mar­ket ...

7 years ago
Financing
China

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline ...

7 years ago
R&D
China

John Kaiser finds next CEO role at Duke spin­out Evecx­ia; Im­muno­core vet Namir Has­san moves to I/O biotech Zel­lu­na

7 years ago
Peer Review

No­vo Nordisk buys uni­ver­si­ty spin­out Ziy­lo — adding a po­ten­tial rem­e­dy for hy­po­glycemia to its di­a­betes pipeline

7 years ago
Deals

For­mer head of Chi­na's FDA boot­ed in wake of sear­ing vac­cine scan­dal as lead­ers im­pose 'se­vere pun­ish­men­t'

7 years ago
R&D
China

Der­ma­tol­ogy biotech Blue­ber­ry Ther­a­peu­tics banks $12M Se­ries B — and new part­ners in Asia

7 years ago
Financing

Gilead los­es key patent claims for So­val­di in Chi­na, open­ing door to ear­li­er gener­ic en­try

7 years ago
China

Mus­tang Bio ven­tures in­to gene ther­a­py, li­cens­ing 'bub­ble boy dis­ease' treat­ment from St. Jude

7 years ago
R&D
Pharma

PARP in­hibitors for ALS? Penn re­searchers post promis­ing finds in brain dis­ease

7 years ago
Discovery

Mer­ck vet Thomas Can­nell takes the reins at Sesen Bio; Post-tur­bu­lence, Rock­well Med­ical ap­points new CEO

7 years ago
Peer Review

Chi­na reg­u­la­tors of­fer VIP treat­ment for 48 over­seas drugs they're ready to hus­tle up with ac­cel­er­at­ed re­views

7 years ago
China
Pharma

Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

7 years ago
Financing
China
First page Previous page 112113114115116117118 Next page Last page
A service from the Financial Times